Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric cancer

Autoři: Shingo Togano aff001;  Masakazu Yashiro aff001;  Yuichiro Miki aff001;  Yurie Yamamato aff002;  Tomohiro Sera aff001;  Yukako Kushitani aff001;  Atsushi Sugimoto aff001;  Shuhei Kushiyama aff001;  Sadaaki Nishimura aff001;  Kenji Kuroda aff001;  Tomohisa Okuno aff001;  Mami Yoshii aff001;  Tatsuro Tamura aff001;  Takahiro Toyokawa aff001;  Hiroaki Tanaka aff001;  Kazuya Muguruma aff001;  Sayaka Tanaka aff004;  Masaichi Ohira aff001
Působiště autorů: Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan aff001;  Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan aff002;  Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan aff003;  Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan aff004
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0225958



Peritoneal recurrence is one of the most frequent recurrent diseases in gastric cancer. Although the exposure of cancer cells to the serosal surface is considered a common risk factor for peritoneal recurrence, there are some cases of peritoneal recurrence without infiltration to the serosal surface even after curative surgery. This study sought to clarify the risk factors of peritoneal recurrence in the absence of invasion to the serosal surface.

Materials and methods

Ninety-six patients with gastric cancer who underwent curative surgery were enrolled. In all 96 cases, the depth of tumor invasion was subserosal (T3). The microscopic distance from the tumor invasion front to the serosa (DIFS) was measured using tissue slides by H&E staining and pan-cytokeratin staining. E-cadherin expression was evaluated by immunohistochemical staining.


Among the 96 patients, 16 developed peritoneal recurrence after curative surgery. The DIFS of the tumors with peritoneal recurrence (156±220 μm) was significantly shorter (p = 0.011) than that without peritoneal recurrence (360±478 μm). Peritoneal recurrence was significantly correlated with DIFS ≤234 μm (p = 0.023), but not with E-cadherin expression. The prognosis of DIFS ≤234 μm was significantly poorer than that of DIFS >234 μm (log rank, p = 0.007). A multivariate analysis of the patients' five-year overall survival revealed that DIFS ≤234 μm and lymph node metastasis were significantly correlated with survival (p = 0.005, p = 0.032, respectively).


The measurement of the DIFS might be useful for the prediction of peritoneal recurrence in T3-gastric cancer patients after curative surgery.

Klíčová slova:

Cell staining – Gastric cancer – Lymph nodes – Metastasis – Multivariate analysis – Prognosis – Surgical and invasive medical procedures – Surgical oncology


1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27. Epub 2015/07/17. doi: 10.1001/jamaoncol.2015.0735 26181261; PubMed Central PMCID: PMC4500822.

2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. The New England journal of medicine. 2007;357(18):1810–20. Epub 2007/11/06. doi: 10.1056/NEJMoa072252 17978289

3. Miki Y, Yashiro M, Ando K, Okuno T, Kitayama K, Masuda G, et al. Examination of cancer cells exposed to gastric serosa by serosal stamp cytology plus RT-PCR is useful for the identification of gastric cancer patients at high risk of peritoneal recurrence. Surgical oncology. 2017;26(4):352–8. Epub 2017/11/09. doi: 10.1016/j.suronc.2017.07.008 29113652

4. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87(3):353–7. doi: 10.1046/j.1365-2168.2000.01358.x 10718807

5. Hiratsuka M, Iwanaga T, Furukawa H, Yasuda T, Nakano H, Nakamori S, et al. [Important prognostic factors in surgically treated gastric cancer patients]. Gan To Kagaku Ryoho. 1995;22(5):703–8. 7717727

6. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 1999;178(3):256–62. Epub 1999/10/20. doi: 10.1016/s0002-9610(99)00162-2 10527450

7. Yashiro M, Hirakawa K. Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron. 2010;3(1):127–35. Epub 2011/01/07. doi: 10.1007/s12307-010-0036-5 21209779; PubMed Central PMCID: PMC2990484.

8. Sun F, Feng M, Guan W. Mechanisms of peritoneal dissemination in gastric cancer. Oncology letters. 2017;14(6):6991–8. Epub 2018/01/19. doi: 10.3892/ol.2017.7149 29344127; PubMed Central PMCID: PMC5754894.

9. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018;21(1):144–54. Epub 2017/04/19. doi: 10.1007/s10120-017-0716-7 28417260

10. Gao M, Zhang X, Li D, He P, Tian W, Zeng B. Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma. Oncotarget. 2016;7(51):85502–14. Epub 2016/12/03. doi: 10.18632/oncotarget.13453 27907907; PubMed Central PMCID: PMC5356753.

11. Liang G, Ding M, Lu H, Cao NA, Niu Y, Gao Y, et al. Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncology letters. 2015;10(3):1527–32. Epub 2015/12/02. doi: 10.3892/ol.2015.3475 26622703; PubMed Central PMCID: PMC4533732.

12. Torabizadeh Z, Nosrati A, Sajadi Saravi SN, Yazdani Charati J, Janbabai G. Evaluation of E-cadherin Expression in Gastric Cancer and Its Correlation with Clinicopathologic Parameters. International journal of hematology-oncology and stem cell research. 2017;11(2):158–64. Epub 2017/09/07. 28875011; PubMed Central PMCID: PMC5575728.

13. Yoshida M, Sugino T, Kusafuka K, Nakajima T, Makuuchi R, Tokunaga M, et al. Peritoneal dissemination in early gastric cancer: importance of the lymphatic route. Virchows Arch. 2016;469(2):155–61. Epub 2016/05/26. doi: 10.1007/s00428-016-1960-7 27220762

14. Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T, et al. Peritoneal dissemination of early gastric cancer: report of a case. Surgery today. 2006;36(9):835–8. Epub 2006/08/29. doi: 10.1007/s00595-006-3253-2 16937291

15. Brierley JD, Gospodarowicz MK, Writtekind C. TNM Classification of Malignant Tumours, 8th Edition2016.

16. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12. doi: 10.1007/s10120-011-0041-5 21573743

17. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(33):4387–93. Epub 2011/10/20. doi: 10.1200/jco.2011.36.5908 22010012

18. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012;379(9813):315–21. Epub 2012/01/10. doi: 10.1016/s0140-6736(11)61873-4 22226517

19. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet Oncology. 2014;15(12):1389–96. Epub 2014/12/03. doi: 10.1016/S1470-2045(14)70473-5 25439693

20. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M. Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer. 1996;74(9):1406–12. doi: 10.1038/bjc.1996.556 8912536

21. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer. 1995;72(5):1200–10. doi: 10.1038/bjc.1995.486 7577468

22. Tanaka T, Kumagai K, Shimizu K, Masuo K, Yamagata K. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; extranodal invasion is a significant risk factor for peritoneal metastasis. J Surg Oncol. 2000;75(3):165–71. Epub 2000/11/23. doi: 10.1002/1096-9098(200011)75:3<165::aid-jso3>3.0.co;2-5 11088047

23. Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, et al. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012;106(3):304–10. Epub 2012/01/11. doi: 10.1002/jso.23008 22231933

24. Yonemura Y, Nojima N, Kaji M, Kawamura T, Fushida S, Fujimura T, et al. E-cadherin and c-met expression as a prognostic factor in gastric cancer. Oncol Rep. 1997;4(4):743–8. Epub 1997/07/01. doi: 10.3892/or.4.4.743 21590132

Článek vyšel v časopise


2020 Číslo 1
Nejčtenější tento týden